IN8bio to Host Investor Call at 8:30 AM ET on Tuesday, December 12 to Discuss Updated Clinical Data from Phase 1 Trial of INB-100 in Patients with Leukemia
06 December 2023 - 12:00AM
IN8bio, Inc. (Nasdaq: INAB), a leading clinical-stage
biopharmaceutical company focused on innovative gamma-delta T cell
therapies, today announced the Company will host a conference call
on Tuesday, December 12, 2023 at 8:30 am ET. The event will
highlight data presented at the ASH 65th Annual Meeting in a poster
presentation on December 11, 2023 starting at 6:00 pm PT. The
Company’s INB-100 trial is focused on investigating the potential
of harnessing donor-derived allogeneic gamma-delta T cells for the
treatment of patients with hematological malignancies following
hematopoietic bone marrow transplantation (HSCT).
Speakers on the call will include IN8bio’s
management team, as well as key oncology thought leader Michael
Bishop, MD, Director of the David and Etta Jones Center for
Cellular Therapy at the University of Chicago, who will be
highlighting gamma-delta T cells as a clinical strategy to prevent
relapse of patients with hematological malignancies. Dr. Bishop is
a prominent clinical investigator of acute leukemias, with a focus
on improving transplant outcomes and preventing relapse. He is a
faculty member and a member of the planning committee for the
ASTCT/EBMT Conference on Relapse After Transplant and Cellular
Therapy. Dr. Bishop previously served as a senior investigator and
as the clinical head of stem cell transplantation for the National
Cancer Institute (NCI) at the National Institutes of Health.
Conference Call Details IN8bio
will host a conference call and webcast on Tuesday, December 12,
2023, at 8:30 am ET to review the updated data from the poster
presentation at ASH. The webcast can be accessed here and will also
be available under the “Events and Presentations” section of the
Company’s website at https://investors.in8bio.com. An archived
webcast will be available on the Company’s website following the
event.
About the INB-100 Phase 1
TrialThe Phase 1 clinical trial (NCT03533816) is a
dose-escalation trial of allogeneic derived, gamma-delta T cells
from matched related donors that have been expanded and activated
ex vivo and administered systemically to patients with hematologic
malignancies following HSCT. The single-institution clinical trial
is currently being conducted at The University of Kansas Cancer
Center (KUCC). The primary endpoints of this trial are safety and
tolerability, and secondary endpoints include rates of GvHD,
relapse rate and overall survival.
About IN8bioIN8bio is a
clinical-stage biopharmaceutical company focused on the discovery,
development and commercialization of gamma-delta T cell product
candidates for solid and liquid tumors. Gamma-delta T cells are a
specialized population of T cells that possess unique properties,
including the ability to differentiate between healthy and diseased
tissue. IN8bio’s DeltEx platform employs allogenic, autologous,
iPSC and genetically modified approaches to develop cell therapies,
designed to effectively identify and eradicate tumor cells.
IN8bio has initiated a Phase 2 trial of INB-400
in GBM at multiple centers across the United States and has two
ongoing Phase 1 trials in solid and hematological tumors, including
INB-200 for GBM and INB-100 for patients with hematologic
malignancies undergoing transplantation. IN8bio also has a broad
portfolio of preclinical programs focused on addressing other
hematological and solid tumor cancers. For more information about
IN8bio and its programs, please visit www.IN8bio.com.
Forward Looking StatementsThis press release
may contain forward-looking statements made pursuant to the safe
harbor provisions of the Private Securities Litigation Reform Act
of 1995. These statements may be identified by words such as
“aims,” “anticipates,” “believes,” “could,” “estimates,” “expects,”
“forecasts,” “goal,” “intends,” “may,” “plans,” “possible,”
“potential,” “seeks,” “will” and variations of these words or
similar expressions that are intended to identify forward-looking
statements, although not all forward-looking statements contain
these words. Forward-looking statements in this press release
include, but are not limited to, statements regarding the potential
of harnessing the power of donor-derived allogeneic gamma-delta T
cell for the treatment of patients with hematological malignancies
following HSCT; and the ability of gamma-delta T cells to prevent
relapse of patients with hematological malignancies. IN8bio may not
actually achieve the plans, intentions or expectations disclosed in
these forward-looking statements, and you should not place undue
reliance on these forward-looking statements. Actual results or
events could differ materially from the plans, intentions and
expectations disclosed in these forward-looking statements as a
result of various factors, including: risks to site initiation,
clinical trial commencement, patient enrollment and follow-up, as
well as IN8bio’s ability to meet anticipated deadlines and
milestones; uncertainties inherent in the initiation and completion
of preclinical studies and clinical trials and clinical development
of IN8bio’s product candidates; the risk that IN8bio may not
realize the intended benefits of its DeltEx platform; availability
and timing of results from preclinical studies and clinical trials;
whether the outcomes of preclinical studies will be predictive of
clinical trial results; whether initial or interim results from a
clinical trial will be predictive of the final results of the trial
or the results of future trials; the risk that trials and studies
may be delayed and may not have satisfactory outcomes; potential
adverse effects arising from the testing or use of IN8bio’s product
candidates; expectations for regulatory approvals to conduct trials
or to market products; IN8bio’s reliance on third parties,
including licensors and clinical research organizations; and other
important factors, any of which could cause our actual results to
differ from those contained in the forward-looking statements.
These and other factors are described in greater detail in the
section entitled “Risk Factors” in our Quarterly Report on Form
10-Q filed with the Securities and Exchange Commission (SEC) on
November 9, 2023, as well as in other filings IN8bio may make with
the SEC in the future. Any forward-looking statements contained in
this press release speak only as of the date hereof, and IN8bio
expressly disclaims any obligation to update any forward-looking
statements contained herein, whether because of any new
information, future events, changed circumstances or otherwise,
except as otherwise required by law.
Company Contact:IN8bio,
Inc,Patrick McCall+1 646.600.6GDT (6438)info@IN8bio.com
Investors & Media Contact:Argot
PartnersIN8bio@argotpartners.com
IN8bio (NASDAQ:INAB)
Historical Stock Chart
From May 2024 to Jun 2024
IN8bio (NASDAQ:INAB)
Historical Stock Chart
From Jun 2023 to Jun 2024